Rallybio (RLYB) vs Retension Pharmaceuticals (RTSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 12, 2026.
Summary
Retension Pharmaceuticals is the larger company by market cap ($89.2 million vs $89.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | RLYB | RTSN |
|---|---|---|
| Share price | $16.79 | $11.32 |
| Market cap | $89.20M | $89.22M |
| 1-day change | -1.35% | +7.50% |
| YTD return | +205.94% | — |
| 1-year return | +297.49% | — |
| 5-year return | -87.07% | — |
| P/E ratio (TTM) | 2.10 | — |
| EPS (TTM) | $8.01 | $-2.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.57 | $11.79 |
| 52-week low | $3.67 | $9.66 |
| Distance from 52-week high | -4.46% | -3.99% |
| Average volume | 21.01K | 789.20K |
| Shares outstanding | 5.31M | 7.88M |
| Employees | 7 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Retension Pharmaceuticals
RTSN stock →Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
RLYB vs RTSN FAQ
Which is bigger, Rallybio or Retension Pharmaceuticals?
Retension Pharmaceuticals (RTSN) is larger, with a market capitalization of $89.22M compared with $89.20M for Rallybio (RLYB).
Are Rallybio and Retension Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.